Aberrant crypt foci: The case for inclusion as a biomarker for colon cancer

Cancers

Volumn 2, Issue 3, 2010, Pages 1705-1716

  Wargovich, Michael J ^a   Brown, Vondina R ^a   Morris, Jay ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aberrant crypt foci; Biomarker; Chemoprevention; Colon cancer

Indexed keywords

ABERRANT CRYPT FOCUS; CANCER GROWTH; CANCER PREVENTION; CLINICAL EXAMINATION; COLON CANCER; COLON CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE MARKER; DYSPLASIA; GENE MUTATION; GENE SILENCING; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; MICROSATELLITE INSTABILITY; NONHUMAN; REVIEW;

EID: 79952256046     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2031705     Document Type: Review

References (80)

1. American Cancer Society. Cancer Facts and Figures 2009; American Cancer Society: Atlanta, GA, USA, 2009.
2. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective; World Cancer Research Fund International (WCRF International): London, UK, 2007.
3. Roncucci, L.; Pedroni, M.; Vaccina, F.; Benatti, P.; and, L.M.; Pol, A.D. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif. 2000, 33, 1-18.
4. Bird, R.P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 1987, 37, 147.
5. Bird, R.P.; McLellan, E.A.; Bruce, W.R. Aberrant crypts, putative precancerous lesions, in the study of the role of diet in the aetiology of colon cancer. Cancer Surv. 1989, 8, 189-200.
6. McLellan, E.A.; Bird, R.P. Aberrant Crypts: Potential Preneoplastic Lesions in the Murine Colon. Cancer Res. 1988, 48, 6187-6192.
7. Pretlow, T.P.; Barrow, B.J.; Ashton, W.S.; O'Riordan, M.A.; Pretlow, T.G.; Jurcisek, J.A.; Stellato, T.A. Aberrant Crypts: Putative Preneoplastic Foci in Human Colonic Mucosa. Cancer Res. 1991, 51, 1564-1567.
8. Renehan, A.G.; O'Dwyer, S.T.; Haboubi, N.J.; Potten, C.S. Early cellular events in colorectal carcinogenesis. Colorectal Disease 2002, 4, 76-89.
9. Jass, J.R.; Ajioka, Y.; Radojkovic, M.; Allison, L.J.; Lane, M.R. Failure to detect colonic mucosal hyperproliferation in mutation positive members of a family with hereditary non-polyposis colorectal cancer. Histopathology 1997, 30, 201-207.
10. Stopera, S.A.; Bird, R.P. Immunohistochemical demonstration of mutant p53 tumour suppressor gene product in aberrant crypt foci. Cytobios 1993, 73, 73-88.
11. Lipkin, M.; Deschner, E. Early proliferative changes in intestinal cells. Cancer Res 1976, 36, 2665-2668.
12. Mills, S.J.; Mathers, J.C.; Chapman, P.D.; Burn, J.; Gunn, A. Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. Gut 2001, 48, 41-46.
13. Green, S.E.; Chapman, P.; Burn, J.; Burt, A.D.; Bennett, M.; Appleton, D.R.; Varma, J.S.; Mathers, J.C. Colonic epithelial cell proliferation in hereditary non-polyposis colorectal cancer. Gut 1998, 43, 85-92.
14. Terpstra, O.T.; van Blankenstein, M.; Dees, J.; Eilers, G.A. Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer. Gastroenterology 1987, 92, 704-708.
15. Ponz de Leon, M.; Roncucci, L.; Di Donato, P.; Tassi, L.; Smerieri, O.; Amorico, M.G.; Malagoli, G.; De Maria, D.; Antonioli, A.; Chahin, N.J., et al. Pattern of epithelial cell proliferation in colorectal mucosa of normal subjects and of patients with adenomatous polyps or cancer of the large bowel. Cancer Res. 1988, 48, 4121-4126.
16. Kubben, F.J.; Peeters-Haesevoets, A.; Engels, L.G.; Baeten, C.G.; Schutte, B.; Arends, J.W.; Stockbrugger, R.W.; Blijham, G.H. Proliferating cell nuclear antigen (PCNA): A new marker to study human colonic cell proliferation. Gut 1994, 35, 530-535.
17. Becciolini, A.; Balzi, M.; Faraoni, P.; Tisti, E.; Zappoli Thyrion, G.; Giache, V.; Bandettini, L.; Potten, C.S. Colonic cell proliferation in normal mucosa of patients with colon cancer. Acta Oncol. 1998, 37, 65-71.
18. Fujimitsu, Y.; Nakanishi, H.; Inada, K.; Yamachika, T.; Ichinose, M.; Fukami, H.; Tatematsu, M. Development of aberrant crypt foci involves a fission mechanism as revealed by isolation of aberrant cryypts. Jpn. J. Cancer Res. 1996, 87, 1199-1203.
19. McLellan, E.A.; Medline, A.; Bird, R.P. Sequential Analyses of the Growth and Morphological Characteristics of Aberrant Crypt Foci: Putative Preneoplastic Lesions. Cancer Res. 1991, 51, 5270-5274.
20. Cheng, H.; Bjerknes, M.; Amar, J.; Gardiner, G. Crypt production in nromal and diseased human colonic epithelium. Anat. Rec. 1986, 319, 44.
21. Bird, R.P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett. 1995, 93, 55-71.
22. Orlando, F.A.; Tan, D.; Baltodano, J.D.; Khoury, T.; Gibbs, J.F.; Hassid, V.J.; Ahmed, B.H.; Alrawi, S.J. Aberrant crypt foci as precursors in colorectal cancer progression. J. Surg. Oncol. 2008, 98, 207-213.
23. Gupta, A.K.; Schoen, R.E. Aberrant crypt foci: Are they intermediate endpoints of colon carcinogenesis in humans? Curr. Opin. Gastroenterol. 2009, 25, 59-65.
24. Gupta, A.K.; Pinsky, P.; Rall, C.; Mutch, M.; Dry, S.; Seligson, D.; Schoen, R.E. Reliability and accuracy of the endoscopic appearance in the identification of aberrant crypt foci. Gastrointest. Endosc. 2009, 70, 322-330.
25. Gupta, A.K.; Pretlow, T.P.; Schoen, R.E. Aberrant crypt foci: What we know and what we need to know. Clin. Gastroenterol. Hepatol. 2007, 5, 526-533.
26. Khare, S.; Chaudhary, K.; Bissonnette, M.; Carroll, R. Aberrant crypt foci in colon cancer epidemiology. Methods Mol. Biol. 2009, 472, 373-386.
27. Lance, P.; Hamilton, S.R. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention. Cancer Prev. Res. (Phila Pa) 2008, 1, 4-8.
28. Stevens, R.G.; Pretlow, T.P.; Hurlstone, D.P.; Giardina, C.; Rosenberg, D.W. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial". Cancer Prev. Res. (Phila Pa) 2008, 1, 215-216; author reply 216.
29. J. Azoxymethane-induced rat aberrant crypt foci: Relevance in studying chemoprevention of colon cancer. World J. Gastroenterol. 2008, 14, 6632-6635.
30. Wargovich, M.J.; Chen, C.D.; Jimenez, A.; Steele, V.E.; Velasco, M.; Stephens, L.C.; Price, R.; Gray, K.; Kelloff, G.J. Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 355-360.
31. Paulsen, J.E.; Steffensen, I.-L.; Namork, E.; Alexander, J. Scanning electron microscopy of aberrant crypt foci in rat colon. Carcinogenesis 1994, 15, 2371-2373.
32. Fenoglio-Preiser, C.M.; Noffsinger, A. Review Article: Aberrant Crypt Foci: A Review. Toxicol. Pathol. 1999, 27, 632-642.
33. Bird, R.P.; Good, C.K. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol. Lett. 2000, 112-113, 395-402.
34. Mori, H.; Hata, K.; Yamada, Y.; Kuno, T.; Hara, A. Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem. Biol. Interact. 2005, 155, 1-9.
35. Caderni, G.; Femia, A.P.; Giannini, A.; Favuzza, A.; Luceri, C.; Salvadori, M.; Dolara, P. Identification of Mucin-depleted Foci in the Unsectioned Colon of Azoxymethane-treated Rats. Cancer Res. 2003, 63, 2388-2392.
36. Bara, J.; Forgue-Lafitte, M.E.; Maurin, N.; Flejou, J.F.; Zimber, A. Abnormal expression of gastric mucin in human and rat aberrant crypt foci during colon carcinogenesis. Tumour Biol. 2003, 24, 109-115.
37. Femia, A.P.; Paulsen, J.E.; Dolara, P.; Alexander, J.; Caderni, G. Correspondence between flat aberrant crypt foci and mucin-depleted foci in rodent colon carcinogenesis. Anticancer. Res. 2008, 28, 3771-3775.
38. Jenab, M.; Chen, J.; Thompson, L.U. Sialomucin production in aberrant crypt foci relates to degree of dysplasia and rate of cell proliferation. Cancer Lett. 2001, 165, 19-25.
39. Femia, A.P.; Giannini, A.; Fazi, M.; Tarquini, E.; Salvadori, M.; Roncucci, L.; Tonelli, F.; Dolara, P.; Caderni, G. Identification of mucin depleted foci in the human colon. Cancer Prev. Res. (Phila Pa) 2008, 1, 562-567.
40. Mori, H.; Yamada, Y.; Kuno, T.; Hirose, Y. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis. Mutat. Res. 2004, 566, 191-208.
41. Paulsen, J.E.; Knutsen, H.; Olstorn, H.B.; Loberg, E.M.; Alexander, J. Identification of flat dysplastic aberrant crypt foci in the colon of azoxymethane-treated A/J mice. Int. J. Cancer 2006, 118, 540-546.
42. Cheng, L.; Mao-De, L. Aberrant crypt foci as microscopic precursurs of colorectal cancer. World J. Gastroenterol. 2003, 9, 2642-2649.
43. Pretlow, T.P.; O'Riordan, M.A.; Pretlow, T.G.; Stellato, T.A. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J. Cell. Biochem. Suppl. 1992, 16G, 55-62.
44. Alrawi, S.J.; Schiff, M.; Carroll, R.E.; Dayton, M.; Gibbs, J.F.; Kulavlat, M.; Tan, D.; Berman, K.; Stoler, D.L.; Anderson, G.R. Aberrant Crypt Foci. Anticancer Res. 2006, 26, 107-119.
45. Heinen, C.D.; Shivapurkar, N.; Tang, Z.; Groden, J.; Alabaster, O. Microsatellite Instability in Aberrant Crypt Foci from Human Colons. Cancer Res. 1996, 56, 5339-5341.
46. Shivapurkar, N.; Huang, L.; Ruggeri, B.; Swalsky, P.A.; Bakker, A.; Finkelstein, S.; Frost, A.; Silverberg, S. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Cancer Lett. 1997, 115, 39-46.
47. Sena, P.; Saviano, M.; Monni, S.; Losi, L.; Roncucci, L.; Marzona, L.; Pol, A.D. Subcellular localization of [beta]-catenin and APC proteins in colorectal preneoplastic and neoplastic lesions. Cancer Lett. 2006, 241, 203-212.
48. Nascimbeni, R.; Villanacci, V.; Mariani, P.P.; Di Betta, E.; Ghirardi, M.; Donato, F.; Salerni, B. Aberrant Crypt Foci in the Human Colon: Frequency and Histologic Patterns in Patients With Colorectal Cancer or Diverticular Disease. Am. J. Surg. Path. 1999, 23, 1256.
49. Chan, A.O.-O.; Broaddus, R.R.; Houlihan, P.S.; Issa, J.-P.J.; Hamilton, S.R.; Rashid, A. CpG Island Methylation in Aberrant Crypt Foci of the Colorectum. Am. J. Pathol. 2002, 160, 1823-1830.
50. Coral, V.A.W.; Takeshi, K.; Michael, D.W.; Barbara, A.L.; Joanne, Y.; Jeremy, R.J. DNA methylation patterns in adenomas from FAP, multiple adenoma and sporadic colorectal carcinoma patients. Int. J. Cancer 2006, 118, 907-915.
51. Takahashi, M.; Mutoh, M.; Kawamori, T.; Sugimura, T.; Wakabayashi, K. Altered expression of {beta}-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 2000, 21, 1319-1327.
52. Takahashi, M.; Fukuda, K.; Sugimura, T.; Wakabayashi, K. {beta}-Catenin Is Frequently Mutated and Demonstrates Altered Cellular Location in Azoxymethane-induced Rat Colon Tumors. Cancer Res. 1998, 58, 42-46.
53. Tsujii, M.; DuBois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83, 493-501.
54. Kazanov, D.; Shapira, I.; Pick, M.; Kolker, O.; Liberman, E.; Deutsch, V.; Strier, L.; Dvory-Sobol, H.; Kunik, T.; Arber, N. Oncogenic Transformation of Normal Enterocytes by Overexpression of Cyclin D1. Dig. Dis. Sci. 2003, 48, 1251-1261.
55. Bala, S.; Peltomaki, P. CYCLIN D1 as a Genetic Modifier in Hereditary Nonpolyposis Colorectal Cancer. Cancer Res. 2001, 61, 6042-6045.
56. Peltomäki, P. DNA mismatch repair and cancer. Mutat. Res./Rev. Mutat. Res. 2001, 488, 77-85.
57. Duval, A.; Rolland, S.; Tubacher, E.; Bui, H.; Thomas, G.; Hamelin, R. The Human T-Cell Transcription Factor-4 Gene: Structure, Extensive Characterization of Alternative Splicings, and Mutational Analysis in Colorectal Cancer Cell Lines. Cancer Res. 2000, 60, 3872-3879.
58. Toyota, M.; Itoh, F.; Imai, K. DNA methylation and gastrointestinal malignancies: Functional consequences and clinical implications. J. Gastroenterol. 2000, 35, 727-734.
59. Pedroni, M.; Sala, E.; Scarselli, A.; Borghi, F.; Menigatti, M.; Benatti, P.; Percesepe, A.; Rossi, G.; Foroni, M.; Losi, L.; Di Gregorio, C.; Anto De, P.; Nascimbeni, R.; Di Betta, E.; Salerni, B.; Ponz de Leon, M.; Roncucci, L. Microsatellite Instability and Mismatch-Repair Protein Expression in Hereditary and Sporadic Colorectal Carcinogenesis. Cancer Res. 2001, 61, 896-899.
60. Liu, T.; Yan, H.; Kuismanen, S.; Percesepe, A.; Bisgaard, M.-L.; Pedroni, M.; Benatti, P.; Kinzler, K.W.; Vogelstein, B.; Ponz de Leon, M.; Peltomaki, P.; Lindblom, A. The Role of hPMS1 and hPMS2 in Predisposing to Colorectal Cancer. Cancer Res. 2001, 61, 7798-7802.
61. Lucci-Cordisco, E.; Rovella, V.; Carrara, S.; Percesepe, A.; Pedroni, M.; Bellacosa, A.; Caluseriu, O.; Forasarig, M.; Anti, M.; Neri, G.; de Leon, M.P.; Viel, A.; Genuardi, M. Mutations of the 'minor' mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Fam. Cancer 2001, 1, 95-101.
62. Luo, L.; Shen, G.-Q.; Stiffler, K.A.; Wang, Q.K.; Pretlow, T.G.; Pretlow, T.P. Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer. Carcinogenesis 2006, 27, 1153-1159.
63. Jones, P.A.; Baylin, S.B. The Epigenomics of Cancer. Cell 2007, 128, 683-692.
64. Rashid, A.; Shen, L.; Morris, J.S.; Issa, J.-P.J.; Hamilton, S.R. CpG Island Methylation in Colorectal Adenomas. Am. J. Pathol. 2001, 159, 1129-1135.
65. Suzuki, H.; Watkins, D.N.; Jair, K.-W.; Schuebel, K.E.; Markowitz, S.D.; Dong Chen, W.; Pretlow, T.P.; Yang, B.; Akiyama, Y.; van Engeland, M.; Toyota, M.; Tokino, T.; Hinoda, Y.; Imai, K.; Herman, J.G.; Baylin, S.B. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004, 36, 417-422.
66. Toyota, M.; Ohe-Toyota, M.; Ahuja, N.; Issa, J.-P.J. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. 2000, 97, 710-715.
67. Wang, L.; Bani-Hani, A.; Montoya, D.P.; Roche, P.C.; Thibodeau, S.N.; Bugart, L.J.; Roberts, L.R. hMLH1 and hMSH2 expression in human hepatocellular carcinoma. Int. J. Oncol. 2001, 19, 567-570.
68. Greenspan, E.J.; Cyr, J.L.; Pleau, D.C.; Levine, J.; Rajan, T.V.; Rosenberg, D.W.; Heinen, C.D. Microsatellite instability in aberrant crypt foci from patients without concurrent colon cancer. Carcinogenesis 2007, 28, 769-776.
69. Takayama, T.; Ohi, M.; Hayashi, T.; Miyanishi, K.; Nobuoka, A.; Nakajima, T.; Satoh, T.; Takimoto, R.; Kato, J.; Sakamaki, S.; Niitsu, Y. Analysis of K-ras, APC, and [beta]-Catenin in Aberrant Crypt Foci in Sporadic Adenoma, Cancer, and Familial Adenomatous Polyposis. Gastroenterol. 2001, 121, 599-611.
70. Corpet, D.E.; Tache, S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr. Cancer 2002, 43, 1-21.
71. Wargovich, M.J.; Jimenez, A.; McKee, K.; Steele, V.E.; Velasco, M.; Woods, J.; Price, R.; Gray, K.; Kelloff, G.J. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 2000, 21, 1149-1155.
72. Steele, V.E.; Moon, R.C.; Lubet, R.A.; Grubbs, C.J.; Reddy, B.S.; Wargovich, M.; McCormick, D.L.; Pereira, M.A.; Crowell, J.A.; Bagheri, D., et al. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J. Cell. Biochem. Suppl. 1994, 20, 32-54.
73. Ochiai, M.; Ushigome, M.; Fujiwara, K.; Ubagai, T.; Kawamori, T.; Sugimura, T.; Nagao, M.; Nakagama, H. Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Am. J. Pathol. 2003, 163, 1607-1614.
74. Qin, X.; Zarkovic, M.; Nakatsuru, Y.; Arai, M.; Oda, H.; Ishikawa, T. DNA adduct formation and assessment of aberrant crypt foci in vivo in the rat colon mucosa after treatment with N-methyl-N-nitrosourea. Carcinogenesis 1994, 15, 851-855.
75. Xu, M.; Chen, R.; Dashwood, R.H. Effect of carcinogen dose fractionation, diet and source of F344 rat on the induction of colonic aberrant crypts by 2-amino-3-methylimidazo[4,5-f]quinoline. Carcinogenesis 1999, 20, 2293-2298.
76. Corpet, D. Chemoprevention Database Colorectal Cancer Prevention. INRA: Paris, France, 2010.
77. Hurlstone, D.P.; Karajeh, M.; Sanders, D.S.; Drew, S.K.; Cross, S.S. Rectal Aberrant Crypt Foci Identified Using High-Magnification-Chromoscopic Colonoscopy: Biomarkers for Flat and Depressed Neoplasia. Am. J. Gastroenterol. 2005, 100, 1283-1289.
78. Takayama, T.; Katsuki, S.; Takahashi, Y.; Ohi, M.; Nojiri, S.; Sakamaki, S.; Kato, J.; Kogawa, K.; Miyake, H.; Niitsu, Y. Aberrant Crypt Foci of the Colon as Precursors of Adenoma and Cancer. N. Engl. J. Med. 1998, 339, 1277-1284.
79. Cho, N.; Redston, M.; Zauber, A.; Carothers, A.; Hornick, J.; Wilton, A.; Sontag, S.; Nishioka, N.; Giardiello, F.; Saltzman, J.; Gostout, C.; Eagle, C.; Hawk, E.; Bertagnolli, M. Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. 2008, 1, 21-31.
80. Suehiro, Y.; Hinoda, Y. Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. Cancer Sci. 2008, 99, 1071-1076.